Official publication of Rawalpindi Medical University
Comparison of Topical Silymarin with Hydroquinone in the Treatment of Melasma
PDF

How to Cite

1.
Sumaira Abdullah, Mahwish Ahmed, Mahvish Aftab Khan, Tayaba Iqbal, Shawana Sharif, Farhat Rehman. Comparison of Topical Silymarin with Hydroquinone in the Treatment of Melasma. JRMC [Internet]. 2022 Mar. 31 [cited 2024 May 26];26(1). Available from: http://www.journalrmc.com/index.php/JRMC/article/view/1778

Abstract

Objective: To compare the efficacy and safety of topical silymarin 0.7% with topical hydroquinone 4% in the treatment of melasma.

Place and Duration: This Randomized Controlled Trial was conducted at dermatology OPD of Akbar Niazi Teaching Hospital, Bara Kahu, Islamabad, in a period of one year from April 2020 to April 2021.

Patients and Methods: Female patients having melasma were included in the study. The severity of melasma was assessed using MASI score. Group A was treated with silymarin 0.7% cream and group B was treated with topical hydroquinone 4% cream. Treatment was given for 3 months and was followed up for the next 3 months to observe relapse. Clinical efficacy was assessed in terms of percent reduction in MASI score from baseline.

Results: The mean age in group A (Silymarin 0.7%)  was 35.13 ± 3.87 and in group B (Hydroquinone 4%)  was 34.16 ± 3.90. Epidermal type of melasma was most common (76.8% vs 62.5%) in both groups. There was no significant (p-value < 0.05) difference between both groups after one and two months treatment but mean MASI score of Hydroquinone 4% group (10.59 ± 5.74) become significantly (p-value < 0.05) less than Silymarin 0.7% group (8.20 ± 4.41) after 3 months. Similar (p-value > 0.05) therapeutic response was observed after one and two months treatment but it become significantly better in Hydroquinone 4% group after three months treatment. Significantly, (P-value < 0.05) higher adverse effects were detected in patients treated with hydroquinone. There was no difference (P-value > 0.05) in recurrence rate and patients satisfaction between both groups.

Conclusion: topical silymarin has equal efficacy for the treatment of melasma with comparatively very less adverse effects as compared to hydroquinone.

https://doi.org/10.37939/jrmc.v26i1.1778
PDF
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright (c) 2022 Sumaira Abdullah, Mahwish Ahmed, Mahvish Aftab Khan, Tayaba Iqbal, Shawana Sharif, Farhat Rehman